News

Data were presented as a late-breaking abstract at the 23rd Congress of the European Academy of Dermatology and Venereology (EADV) meeting in Amsterdam. The results of this study,

Palbociclib selectively inhibits cyclin-dependent kinases (CDKs) 4 and 6 to regain cell cycle control and block tumor cell proliferation. Under the new drug application (NDA), the company is

Perampanel is used as an adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older. The partnership

The research program is part of a recent grant secured by PATH from the Bill & Melinda Gates Foundation to develop a model for improving the production of

The fixed combination capsule Akynzeo is distributed and marketed by Eisai, under license from Switzerland-based Helsinn Healthcare. Oral palonosetron was approved in 2008 and it prevents nausea and

The contract renewal will extend over a five-year horizon. The company began working with the FDA in 2009. Under the terms of the contract, Symphony Health Solutions will

The privately-held Companies being acquired specialize in the development, manufacture and commercialization of complex generic and branded pharmaceutical products. The transaction will provide Impax with a highly-profitable and

In today’s competitive launch environment, biopharmaceutical leaders are utilizing these insights to help them to better understand potential pitfalls and ensure success at market entry. According to research

Drisapersen secured FDA fast track status, making the drug eligible for a rolling review of an NDA and was also granted breakthrough therapy designation in June 2013. Prosensa